Epicrispr Biotechnologies Secures $90 Million in Latest Series C Funding Round

Epicrispr Biotechnologies secured $90 million in its latest Series C, adding another data point to the Healthcare & Life Sciences funding market.

Epicrispr Biotechnologies Raises $90 million in Funding

Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD. The company's lead candidate, EPI-321, is in a Phase I/II trial.

Investors Behind the Funding

The round was backed by damage. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Epicrispr Biotechnologies operates in Healthcare & Life Sciences. Epicrispr Biotechnologies's financing adds to recent private-market activity.

Strategic Use of Funds

Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD.

Looking Ahead

Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Source reference: original announcement/article.